Xenon Pharmaceuticals
XENE
36.41
-0.16
-0.44%
Xenon Pharmaceuticals
US · XENE
#2361 by market cap
Listed 2015
36.41
-0.16
-0.44%
Live - 5344 symbols - heartbeat 98s ago
· 2026-10-08 08:29
Pre-market
36.25
-0.44%
After-hours
36.00
-1.13%
Overnight
36.40
-0.03%
- Market cap
- 3.53B
- P/E (TTM)i
- -7.68
- P/Bi
- 2.84
- EPSi
- -4.36
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on XENE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 106.39% +0.02pp
- Institutions
- 379 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund72.12%
Hedge Fund27.18%
VC/PE Fund3.52%
Public Company1.40%
Insurance Company0.84%
Government Pension Fund0.73%
Private Company0.34%
Family Office/Trust0.26%
Individual/Insider0.16%
Top holders as of 2026-07-31
FMR
10.18% · 9.86M sh
BlackRock
7.77% · 7.52M sh
Avoro Capital Advisors LLC
5.97% · 5.78M sh
T. Rowe Price Group, Inc.
5.59% · 5.42M sh
Polar Capital Holdings Plc
4.72% · 4.57M sh
Driehaus Capital Management LLC
4.56% · 4.42M sh
Janus Henderson Group plc
4.32% · 4.19M sh
Capital Research
3.33% · 3.22M sh
J.P. Morgan Asset Management, Inc.
2.61% · 2.53M sh
State Street Global Advisors
2.03% · 1.97M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 34 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Ian Mortimer | Chief Executive Officer | 0.07% |
| Dawn Svoronos | Lead Independent Director | 0.03% |
| Gary Patou | Independent Director | 0.03% |
| Thomas Kelly | Chief Financial Officer | 0.02% |
| Andrea DiFabio | Chief Legal Officer | 0.01% |
| C. Machado | Independent Director | 0.00% |
| Elizabeth Garofalo | Independent Director | 0.00% |
| Justin Gover | Director | 0.00% |
| Steven Gannon | Independent Director | 0.00% |
| Gillian Cannon | Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Thomas Kelly | Chief Financial Officer | Open Market Acquisition | +15,000 | $37.32 |
| 2026-09-29 | Ian Mortimer | Chief Executive Officer | Open Market Acquisition | +30,000 | $37.38 |
| 2026-08-31 | Dawn Svoronos | Lead Independent Director | Derivative Exercise and Retained | +5,144 | $8.15 |
| 2026-08-27 | Christopher Kenney | Chief Medical Officer | Automatic Disposition | -7,068 | $60.17–60.98 |
| 2026-08-10 | Steven Gannon | Independent Director | Open Market Disposition | -10,000 | $64.06 |
| 2026-06-04 | Gary Patou | Independent Director | Automatic Disposition | -1,322 | $53.14 |
| 2026-06-04 | Gillian Cannon | Director | Automatic Disposition | -1,190 | $53.14 |
| 2026-06-02 | Justin Gover | Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | Justin Gover | Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | Gary Patou | Independent Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | Gary Patou | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | C. Machado | Independent Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | C. Machado | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | Steven Gannon | Independent Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | Steven Gannon | Independent Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | Dawn Svoronos | Lead Independent Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | Dawn Svoronos | Lead Independent Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | Gillian Cannon | Director | Other Derivative Acquisition | +1,593 | -- |
| 2026-06-02 | Gillian Cannon | Director | Other Derivative Acquisition | +10,507 | $53.46 |
| 2026-06-02 | Elizabeth Garofalo | Independent Director | Other Derivative Acquisition | +1,593 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:29:12 · For reference only, not investment advice and not tailored to your situation.